Kathleen D. Scott - 21 Aug 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Chief Financial Officer
Issuer ticker: SPRY
Reported as of: 21 Aug 2025
Net transaction value: -$168,750
SEC form: 4
Accepted by SEC: 22 Aug 2025, 16:30:13 UTC
Prior SEC filing: 22 May 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott

Key filing fact

Kathleen D. Scott filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 22 Aug 2025.

Key facts

This page summarizes Kathleen D. Scott's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Aug 2025, 16:30.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: -$168,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794284 Primary reporting owner

Scott Kathleen D.

Relationship: Chief Financial Officer
Address: C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Signature: /s/ Kathleen Scott
Signature date: 22 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRY transaction

Common Stock

Options Exercise

Transaction value: $18,750
Shares: +12,500
Change %: +124%
Price: $1.50
Shares after: 22,542
Date: 21 Aug 2025
Ownership: Direct
Footnotes: F1

SPRY transaction

Common Stock

Sale

Transaction value: $187,500
Shares: -12,500
Change %: -55%
Price: $15.00
Shares after: 10,042
Date: 21 Aug 2025
Ownership: Direct
Footnotes: F2

SPRY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,250
Date: 21 Aug 2025
Ownership: By Scott 2008 Trust Dated 3/28/08

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -12,500
Change %: -1.7%
Price: $0.000000
Shares after: 739,830
Date: 21 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $1.50
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.

Footnote F2

The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025.

Footnote F3

Immediately exercisable.